View more in
Health

First-in-Human Trial of CLN-081 in EGFR ex 20+ NSCLC Shows Early Promise

cancernetwork.com
 2021-06-04

Cover picture for the articleA phase 1 trial of the investigational agent CLN-081 indicates antitumor activity coupled with a tolerable safety profile as treatment of patients with non–small cell lung cancer and EGFR exon 20 insertion mutations. Systemic therapy with CLN-081 for EGFR exon 20 insertion mutation–positive non–small cell lung cancer (NSCLC) showed early...

www.cancernetwork.com

Comments / 0

Comments / 0